[go: up one dir, main page]

AU2001255168A1 - Compositions and methods for the treatment of immune related diseases - Google Patents

Compositions and methods for the treatment of immune related diseases

Info

Publication number
AU2001255168A1
AU2001255168A1 AU2001255168A AU5516801A AU2001255168A1 AU 2001255168 A1 AU2001255168 A1 AU 2001255168A1 AU 2001255168 A AU2001255168 A AU 2001255168A AU 5516801 A AU5516801 A AU 5516801A AU 2001255168 A1 AU2001255168 A1 AU 2001255168A1
Authority
AU
Australia
Prior art keywords
compositions
treatment
methods
related diseases
immune related
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001255168A
Inventor
Dan L Eaton
Sherman Fong
Audrey Goddard
Paul J Godowski
Christopher J. Grimaldi
Austin L. Gurney
Daniel Tumas
Colin K. Watanabe
William I. Wood
Zemin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/014941 external-priority patent/WO2000073348A2/en
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/en
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2001255168A1 publication Critical patent/AU2001255168A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00Use of cells in diagnostics
    • C12N2503/02Drug screening
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001255168A 2000-03-03 2001-03-01 Compositions and methods for the treatment of immune related diseases Abandoned AU2001255168A1 (en)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US18720200P 2000-03-03 2000-03-03
US60/187,202 2000-03-03
US19101500P 2000-03-21 2000-03-21
US60/191,015 2000-03-21
AU55911/00 2000-05-30
PCT/US2000/014941 WO2000073348A2 (en) 1999-06-02 2000-05-30 Methods and compositions for inhibiting neoplastic cell growth
US20983200P 2000-06-05 2000-06-05
US60/209,832 2000-06-05
AU75730/00 2000-08-24
PCT/US2000/023328 WO2001016318A2 (en) 1999-09-01 2000-08-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US60/000,000 2000-09-15
AU20554/01 2000-12-01
PCT/US2000/032678 WO2001040466A2 (en) 1999-12-01 2000-12-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/006666 WO2001066740A2 (en) 2000-03-03 2001-03-01 Compositions and methods for the treatment of immune related diseases

Publications (1)

Publication Number Publication Date
AU2001255168A1 true AU2001255168A1 (en) 2001-09-17

Family

ID=27485932

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001255168A Abandoned AU2001255168A1 (en) 2000-03-03 2001-03-01 Compositions and methods for the treatment of immune related diseases

Country Status (2)

Country Link
AU (1) AU2001255168A1 (en)
WO (1) WO2001066740A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094570B2 (en) 2003-03-11 2006-08-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
EP1191035A3 (en) * 2000-09-25 2002-04-17 Schering Aktiengesellschaft Three members of the cytokin-receptor class II family
MXPA03006218A (en) 2001-01-12 2004-09-13 Inst Genetics Llc Type 2 ctokine receptor and nucleic acids encoding same.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5383498A (en) * 1996-12-05 1998-06-29 Human Genome Sciences, Inc. Human chemokine beta-13
WO2000012708A2 (en) * 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
WO2000078961A1 (en) * 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1998045437A2 (en) * 1997-04-10 1998-10-15 Genetics Institute, Inc. SECRETED EXPRESSED SEQUENCE TAGS (sESTs)
WO1999006548A2 (en) * 1997-08-01 1999-02-11 Genset 5'ESTs FOR NON TISSUE SPECIFIC SECRETED PROTEINS
WO1999025825A2 (en) * 1997-11-13 1999-05-27 Genset EXTENDED cDNAs FOR SECRETED PROTEINS
EP1053319A2 (en) * 1998-01-28 2000-11-22 Chiron Corporation Human genes and gene expression products ii
US20020102604A1 (en) * 1999-12-08 2002-08-01 Milne Edwards Jean-Baptiste Dumas Full-length human cDNAs encoding potentially secreted proteins
CA2343696A1 (en) * 1998-09-25 2000-04-06 Incyte Pharmaceuticals, Inc. Membrane-associated organizational proteins
CA2373915A1 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EP1067182A3 (en) * 1999-07-08 2001-11-21 Helix Research Institute Secretory protein or membrane protein
JP3951035B2 (en) * 1999-09-01 2007-08-01 ジェネンテック・インコーポレーテッド Secreted and transmembrane polypeptides and nucleic acids encoding them
EP2228446A1 (en) * 1999-12-01 2010-09-15 Genentech, Inc. Secreted and transmembrane polypeptieds and nucleic acids encoding the same

Also Published As

Publication number Publication date
WO2001066740A3 (en) 2002-09-19
WO2001066740A2 (en) 2001-09-13

Similar Documents

Publication Publication Date Title
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
EP1572116A4 (en) Compositions and methods for the treatment of immune related diseases
EP1576137A4 (en) Compositions and methods for the treatment of immune related diseases
AU2002324914A1 (en) Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
IL145470A0 (en) Compositions for the treatment of immune diseases
AU7722600A (en) Compositions and methods for the diagnosis and treatment of immune disorders
AU6147401A (en) Compositions and methods for the treatment of cancer
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
EP1560593A4 (en) Novel composition and methods for the treatment of immune related diseases
AU2002352533A1 (en) Methods and compositions for treatment of gastric diseases
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
AU5309600A (en) Compositions and methods for the treatment and diagnosis of immune disorders
HUP0302718A3 (en) Methods and compositions for the treatment of diseases of the eye
EP1578373A4 (en) Novel compositions and methods for the treatment of immune related diseases
AU9395998A (en) Compositions and methods for the treatment of immune related diseases
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
WO2004024076A8 (en) Novel compositions and methods for the treatment of immune related diseases
EP1472273A4 (en) Compositions and methods for the treatment of immune related diseases
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications